Bristol Myers Squibb research reveals atomic structure of protein receptor CD47
New Bristol Myers Squibb research has revealed details about the structure of the protein receptor CD47, which helps protect cells from the human immune system.
List view / Grid view
New Bristol Myers Squibb research has revealed details about the structure of the protein receptor CD47, which helps protect cells from the human immune system.
The biotechnology company Genmab announced today the appointment of Judith Klimovsky, MD, as Executive Vice President and Chief Development Officer.
25 July 2016 | By Niamh Louise Marriott, Digital Content Producer
AbbVie and Bristol-Myers Squibb Company today announced a clinical trial collaboration to evaluate the safety, tolerability and efficacy of AbbVie’s investigational biomarker-specific antibody drug conjugate Rova-T...
23 March 2016 | By Victoria White
Padlock Therapeutics is a private biotechnology company dedicated to creating new medicines to treat destructive autoimmune diseases...
13 March 2016 | By Victoria White
A group of researchers has taken a step toward a male contraceptive pill by tweaking some experimental compounds that show promise...
7 March 2016 | By Victoria White
LabCentral is an innovative, shared laboratory space designed as a launch pad for life-sciences and biotech startups...
16 February 2016 | By Victoria White
As part of the I-O RPM programme, Bristol-Myers Squibb and Dana-Farber Cancer Institute will conduct a range of early phase clinical studies...
28 January 2016 | By Victoria White
The ADDoPT project addresses the key challenge of getting new innovative medicines to market in the quickest and most cost-effective way...
5 January 2016 | By Victoria White
Oncodesign and Bristol-Myers Squibb have entered into a strategic collaboration to discover, develop and commercialise novel macrocyclic compounds...
14 December 2015 | By Victoria White
Bristol-Myers Squibb and the David Geffen School of Medicine at UCLA will conduct a range of early phase clinical studies as part of the I-O RPM research programme...
24 November 2015 | By Victoria White
The companies have said they will focus is on immuno-oncology, one of the hottest and most dynamic areas in biotechnology...
25 September 2015 | By Victoria White
Bristol-Myers Squibb and Moffitt will conduct a range of early phase clinical studies, including clinical investigations by young investigators to strengthen their development as clinical research scientists...
1 September 2015 | By Charlotte Batchelor
Bristol-Myers Squibb Company and QIMR Berghofer Medical Research Institute have signed a research collaboration and license agreement to discover novel therapeutic antibodies against an undisclosed immuno-oncology...
15 July 2015 | By Victoria White
MUSC and Bristol-Myers Squibb have entered into a research collaboration focused on fibrotic diseases, including scleroderma and renal fibrosis...
25 June 2015 | By Victoria White
Bristol-Myers Squibb Company has announced important next steps in the evolution of the Company’s R&D organisation...